Pyxis pancreatic cancer candidate PYX-201 given Orphan Drug status

• The US FDA has granted Orphan Drug designation to Pyxis Oncology's (NASDAQ:PYXS) PYX-201 for pancreatic cancer.
• Dosing in a phase 1 trial has already begun for the antibody-drug conjugate.
• The company anticipates preliminary data later this year or in early 2024.
• Pyxis said that PYX-201 could also be potentially indicated for breast, head and neck, lung, and thyroid cancers.

More on Pyxis

• Pyxis Oncology: Cashed Up And Entering The Clinic

• Pfizer-backed Pyxis hits 52-week high to cross $200M market cap